Romain Marignier1, Alvaro Cobo Calvo, Sandra Vukusic. 1. aSclérose en plaques, pathologies de la myéline et neuro-inflammation, Hospices Civils de Lyon bCentre de Recherche en Neurosciences de Lyon, Inserm U1028 CNRS UMR5292, FLUID team, Faculté de Médecine Laennec cObservatoire Français de la Sclérose en Plaques (OFSEP), Lyon, France.
Abstract
PURPOSE OF REVIEW: The discovery of highly specific auto-antibodies directed against the water channel aquaporin 4 was a quantum leap in the definition, classification and management of neuromyelitis optica (NMO). Herein, we propose an update on epidemiological, clinical and therapeutic advances in the field, underlining unmet needs. RECENT FINDINGS: Large-scale epidemiological studies have recently provided a more precise evaluation of NMO prevalence and a better stratification regarding ethnicity and sex. New criteria have been proposed for so-called NMO spectrum disorders (NMOSD) and their relevance is currently being assessed. The identification of a new clinical entity associated to antibodies against myelin oligodendrocyte glycoprotein questions the border of NMOSD. SUMMARY: The concept of NMOSD is opening a new era in clinical practice, allowing an easier and more homogeneous diagnosis and an increase in newly identified cases. This will facilitate clinical studies and support new therapeutic trial. Future researches should focus on the position of seronegative NMOSD and myelin oligodendrocyte glycoprotein-IgG disorders in the field and on promising strategies, including the immune tolerisation approaches, to eventually cure NMO.
PURPOSE OF REVIEW: The discovery of highly specific auto-antibodies directed against the water channel aquaporin 4 was a quantum leap in the definition, classification and management of neuromyelitis optica (NMO). Herein, we propose an update on epidemiological, clinical and therapeutic advances in the field, underlining unmet needs. RECENT FINDINGS: Large-scale epidemiological studies have recently provided a more precise evaluation of NMO prevalence and a better stratification regarding ethnicity and sex. New criteria have been proposed for so-called NMO spectrum disorders (NMOSD) and their relevance is currently being assessed. The identification of a new clinical entity associated to antibodies against myelin oligodendrocyte glycoprotein questions the border of NMOSD. SUMMARY: The concept of NMOSD is opening a new era in clinical practice, allowing an easier and more homogeneous diagnosis and an increase in newly identified cases. This will facilitate clinical studies and support new therapeutic trial. Future researches should focus on the position of seronegative NMOSD and myelin oligodendrocyte glycoprotein-IgG disorders in the field and on promising strategies, including the immune tolerisation approaches, to eventually cure NMO.
Authors: Yael Hacohen; Yu Yi Wong; Christian Lechner; Maciej Jurynczyk; Sukhvir Wright; Bahadir Konuskan; Judith Kalser; Anne Lise Poulat; Helene Maurey; Esther Ganelin-Cohen; Evangeline Wassmer; Chery Hemingway; Rob Forsyth; Eva Maria Hennes; M Isabel Leite; Olga Ciccarelli; Banu Anlar; Rogier Hintzen; Romain Marignier; Jacqueline Palace; Matthias Baumann; Kevin Rostásy; Rinze Neuteboom; Kumaran Deiva; Ming Lim Journal: JAMA Neurol Date: 2018-04-01 Impact factor: 18.302
Authors: Lawrence J Cook; John W Rose; Jessica S Alvey; Anna Marie Jolley; Renee Kuhn; Brie Marron; Melissa Pederson; Rene Enriquez; Jeff Yearley; Stephen McKechnie; May H Han; Anna J Tomczak; Michael Levy; Maureen A Mealy; Jessica Coleman; Jeffrey L Bennett; Ruth Johnson; Myka Barnes-Garcia; Anthony L Traboulsee; Robert L Carruthers; Lisa Eunyoung Lee; Julia J Schubert; Katrina McMullen; Ilya Kister; Zoe Rimler; Allyson Reid; Nancy L Sicotte; Sarah M Planchon; Jeffrey A Cohen; Diane Ivancic; Jennifer L Sedlak; Ilana Katz Sand; Pavle Repovic; Lilyana Amezcua; Ana Pruitt; Erika Amundson; Tanuja Chitnis; Devin S Mullin; Eric C Klawiter; Andrew W Russo; Claire S Riley; Kaho B Onomichi; Libby Levine; Katherine E Nelson; Nancy M Nealon; Casey Engel; Mason Kruse-Hoyer; Melanie Marcille; Leticia Tornes; Anne Rumpf; Angela Greer; Megan Kenneally Behne; Renee R Rodriguez; Daniel W Behne; Derek W Blackway; Brian Coords; Terrence F Blaschke; Judy Sheard; Terry J Smith; Jacinta M Behne; Michael R Yeaman Journal: Neurol Neuroimmunol Neuroinflamm Date: 2019-06-28
Authors: Janine Beekman; Aysha Keisler; Omar Pedraza; Masayuki Haramura; Athos Gianella-Borradori; Eliezer Katz; John N Ratchford; Gerard Barron; Lawrence J Cook; Jacinta M Behne; Terrence F Blaschke; Terry J Smith; Michael R Yeaman Journal: Neurol Neuroimmunol Neuroinflamm Date: 2019-06-20